Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01666600
Other study ID # NONK-3/NOA-12
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received July 12, 2012
Last updated October 30, 2017
Start date August 2012
Est. completion date September 2017

Study information

Verified date October 2017
Source University Hospital Heidelberg
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with glioblastoma at first or second progression who have failed standard treatment that must have included radiochemotherapy with temozolomide and who are a candidate for a reirradiation can be included into the trial. In the phase I part the minimal tolerated dose (MTD)of BIBF 1120 in combination with radiotherapy will be investigated. Subjects in phase II will be randomised to receive reirradiation alone or reirradiation + 2 x MTD BIBF1120.


Recruitment information / eligibility

Status Terminated
Enrollment 63
Est. completion date September 2017
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male and female patients with a recurrence / progression of glioblastoma either not being eligible for tumour resection or having macroscopic residual tumour after resection of the recurrence

- Diagnosis of glioblastoma must be proven histologically and progress must be documented by MRI. MRI images must not be older than 2 weeks before first dosing/start of RT

- Not more than two prior therapy regimens including one or two resections, one or two chemotherapies (one temozolomide containing concomitant to radiotherapy) and one radiotherapy (RT) for the brain tumour

- Previous irradiation therapy of the primary tumour with a maximal dose of 60 Gy; at least 8 months since the end of preirradiation

- Candidate for reirradiation with recurrent tumour visible on MRIT1 (Gd) and with the largest diameter measuring 1 cm to 5 cm

- Informed consent

- Age = 18 years, smoking or non-smoking, of any ethnic origin

- Karnofsky performance index (KPI) = 60%

- Neutrophile counts > 1500/µl / Platelet counts > 80.000/µl /Haemoglobin > 10 g/dl / Serum creatinine < 1.5-fold upper normal range / Bilirubin, AST or ALT < 2,5-fold upper normal range unless attributed to anticonvulsants / Alkaline phosphatase < 2,5-fold upper normal range

- Adequate contraception

- If on steroids, stable or decreasing treatment with steroids within 5 days before treatment start

Exclusion Criteria:

- More than one RT of brain, prior first radiotherapy with more than 60 Gy

- Cumulative total dose on the optical chiasm >54 Gy for 2 Gy/fraction, a/ß=2

- Prior treatment with bevacizumab, iodine seeds and/or brachytherapy

- Unable to undergo MRI

- Past medical history of diseases with poor prognosis according to the judgement of the Investigator, e.g. severe coronary heart disease, severe diabetes, immune deficiency, residual deficits after stroke, severe mental retardation

- HIV or hepatitis infection

- Pregnancy or breast feeding

- Treatment within any other clinical trial parallel to the treatment phase of the current study or within 30 days before inclusion

- Known coronary artery disease, significant cardiac arrhythmias or severe congestive heart failure (NYHA class III - IV)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BIBF 1120
BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
Radiation:
radiotherapy
36 Gy, 2 Gy / fraction, 18 fractions

Locations

Country Name City State
Germany University Hospital Heidelberg, Department of Neurooncology Heidelberg Baden-Württemberg
Germany University Hospital Heidelberg, Department of Pharmacology Heidelberg Baden-Württemberg

Sponsors (1)

Lead Sponsor Collaborator
Prof. Dr. Wolfgang Wick

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximal tolerated dose of BIBF 1120 in combination with reirradiation (Phase I) day 0, 8, 15 and 17 post-dose during phase I
Secondary Number of participants with adverse events as a measure of safety and tolerability of BIBF1120 Up to 90 days follow-up
Secondary Progression-free survival Time from randomization until death or disease progression
Secondary Objective response rates (OR) Time from randomization until response
Secondary Overall survival Time from randomization until death
Secondary Quality of life as determined by EORTC QLQ-C15 PAL and the EORTC brain module QLQ-BN 20 Screening and 6-weekly after radiotherapy
Secondary Cognitive function determined by MMSE Screening and 6-weekly after end of radiotherapy
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05023551 - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma Early Phase 1
Recruiting NCT06059690 - Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells Phase 1/Phase 2
Recruiting NCT04116411 - A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients Phase 2
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Completed NCT00038493 - Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Recruiting NCT01923922 - CT Perfusion in the Prognostication of Cerebral High Grade Glioma N/A
Completed NCT01956734 - Virus DNX2401 and Temozolomide in Recurrent Glioblastoma Phase 1
Completed NCT01301430 - Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. Phase 1/Phase 2
Completed NCT01402063 - PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation Phase 2
Suspended NCT01386710 - Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma Phase 1/Phase 2
Active, not recruiting NCT00995007 - A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Phase 2
Terminated NCT01044966 - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Phase 1/Phase 2
Terminated NCT00990496 - A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) Phase 1
Completed NCT00402116 - Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Phase 1/Phase 2
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Completed NCT00504660 - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients Phase 2
Recruiting NCT05366179 - Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc Phase 1